Introduction
Three platinum compounds currently in use worldwide -cisplatin, carboplatin, and oxaliplatin ( Figure 1 ) -have been developed with crucial support from the United States NCI, including screening by the NCI's 60-cell line panel (NCI60 screen) (1) . This process, together with the NCI COMPARE program, identified clear differences in activity profiles and mechanisms of action between platinum compounds, thus enabling the grouping of platinum compounds according to such characteristics (2) . The cisplatin activity profile is similar to that of other diammineplatinum(II) compounds and to alkylating agents such as melphalan and camptothecin analogs. The oxaliplatin activity profile is similar to that of other platinum compounds containing the R,R-1,2diaminocyclohexane ligand, including the platinum(IV) drug tetraplatin, and is also similar to those of acridines, organic compounds currently being developed as anticancer drugs (2) .
Other classes of platinum compounds with activity different from cisplatin, oxaliplatin, or carboplatin have been defined on the basis of the NCI60 screen. The activity of the platinum-pyridines defines one group, into which some polyplatinum compounds including the clinically tested BBR3464 can be classified (3, 4) . The platinum-silanes are another distinct group. Cells resistant to compounds from one group are commonly not cross-resistant to compounds from another. Similarly, because of the different mechanisms of action for each type of compound, it is possible for compounds of different groups to be used in combination with synergistic results, an example being the synergistic effect of combining cisplatin and oxaliplatin (2) . The development of platinum compounds with mechanisms of action different from those of platinum-based drugs already on the market should facilitate identification of candidate compounds that are active in cancers for which cisplatin, carboplatin, or oxaliplatin are inactive. Unique mechanisms of action may derive from the mode of cellular uptake of the compound (5) , preferential localization of the platinum compound to a specific body organ or cell organelle (6) , manipulation of the cellular response to enhance cytotoxicity (7) , or the prevention or retardation of drug inactivation by biotransformation, as occurs for platinum(IV) prodrugs (8) (9) (10) .
Pyriplatin is a monofunctional, cationic platinum(II) compound that has previously shown antitumor activity in mice (11) , and which forms only a single covalent bond with DNA, unlike cisplatin, carboplatin, or oxaliplatin, which bind in a bidentate manner. Besides of this non-traditional structure, there is also evidence for a unique cellular mode of pyriplatin uptake that differs from the uptake of cisplatin or oxaliplatin.
Pyriplatin is an outstanding substrate for the organic cation transporters (OCT) 1 and 2 (12, 13) , which are associated with improved oxaliplatin uptake (14) . Additionally, OCT1 has been identified as important to the pharmacokinetics and tissue distribution of pyriplatin (12) . The mechanism of RNA polymerase II inhibition by pyriplatin-DNA adducts is dramatically different from the inhibition seen with cisplatin-DNA adducts (15) , and the low nucleotide excision repair rates of the pyriplatin-DNA adduct, coupled with its inhibition of RNA polymerase II (13) , are very likely important to the cytotoxic mechanism of action. The aim of the present study was to further characterize pyriplatin in vitro with direct comparison to cisplatin and oxaliplatin to gain insight into the mechanism of action and potential clinical applications for pyriplatin. We investigated cellular and molecular changes induced by pyriplatin in order to determine possible response biomarkers and predictive factors of pyriplatin activity. The effects of combining pyriplatin with several anticancer drugs in current clinical use were also investigated.
Materials and Methods

Cell lines
All cell lines were obtained from the ATCC (Rockville, MD), and NCI cell collections. Cells were grown as monolayers in RPMI medium supplemented with 10% fetal calf serum (Invitrogen, Cergy-Pontoise, France), 2 mM glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin. Cells were split twice a week using trypsin/EDTA (0.25%/0.02%; Invitrogen, Cergy-Pontoise, France) and seeded at a concentration of 2.5 x 10 4 cells/mL. All cell lines were tested regularly for Mycoplasma contamination by PCR using a Stratagene kit (La Jolla, CA).
Single agent evaluation
Pyriplatin was submitted to the National Cancer Institute (USA) for single agent, single dose testing in 2008. For evaluations performed in our laboratory, cells were seeded at 2 x 10 3 cells/well in 96-well plates and treated 24 h later with increasing concentrations of cisplatin, oxaliplatin, or pyriplatin. After 1, 2, 5, 24, or 72 h of incubation, the cells were washed and post-incubated in platinum-free medium for 72 h (after 1, 2, or 5 h) or 48 h (after 24 or 72 h). Growth inhibition was then determined by the MTT assay (16) . Absorption at 560 nm of the control wells containing untreated cells was defined as 100% and the viability of treated samples was expressed as a percentage of the control.
Cell cycle analysis
Exponentially growing MCF7 or HCT-116 cells were treated for 24 h with cisplatin, oxaliplatin, or pyriplatin at the IC 50 concentrations (Table 1) . At the end of treatment and following the 24, 48, or 72 h drug-washout period, the cells were counted, fixed in 70% cold ethanol, and kept at 4°C. The cells were washed with cold PBS and stained with 5 µg/mL propidium iodide in PBS and 12.5 µL/mL RNAse A. Flow cytometric cell cycle analysis was performed on a minimum of 2 x 10 4 cells per sample on a FACS Calibur instrument (Becton Dickinson, Sunnyvale, CA). A 488 nm laser and a dichroic mirror (570 nm) were used and fluorescence emission was detected using a filter for 620 + 35 nm.
Evaluation of apoptosis
HCT-116 or MCF7 cells were harvested following 24 h treatment with platinum compounds at IC 50 concentrations and 0, 24, 48, or 72 h of incubation in platinum-free medium. Cells were washed once with cold PBS, then pelleted and resuspended in 100 µL of a staining buffer containing Annexin V-FITC and 0.5 µg propidium iodide.
Fluorescence analysis by flow cytometry was performed after 15-minute incubation in the dark and dilution of the sample to 500 µL.
Western blotting
HOP-62 cells were treated for 24 h at the IC 50 concentrations of pyriplatin, oxaliplatin, or cisplatin. The platinum-containing medium was removed and cells were lysed either immediately or 24, 48, or 72 h after removal of the platinum-containing medium. 
Combination evaluation
Antiproliferative effects of pyriplatin, cisplatin or oxaliplatin in combination with paclitaxel, gemcitabine, SN38, cisplatin, or 5-fluorouracil were investigated in the ovarian cancer line OVCAR-3 and the colon cancer line HT29. Combination studies were performed as described (17, 18) . Briefly, cells were seeded at 2 x 10 3 cells/well in 96well plates and incubated for 24 h prior to treatment. The combination experiments were performed on three different schedules. Cells were either treated with platinum for 24 h followed by the combination drug for 24 h, treated with the combination drug for 24 h followed by platinum for 24 h, or treated for 24 h with pyriplatin and the combination drug simultaneously. Drug and platinum concentrations from IC 20 to IC 60 were used. Antiproliferative effects were evaluated by the MTT assay and analyzed using the Chou and Talalay method which is based on the median-effect principle (19) and the concentration-effect analysis CalcuSyn software (Biosoft, Cambridge, UK). A combination index (CI) of <1 indicates synergy, a value of 1 indicates additive effects, and a value >1 indicates antagonism.
Measurement of platinum content
HCT-116 cells were incubated for 2 or 24 h with 10 µM cisplatin, oxaliplatin, or pyriplatin. A time course of 2 h platinum exposure followed by a 22 h incubation in platinum-free medium (2/22 schedule) was also evaluated. After trypsinization, cytosol and nuclei were separated in a hypotonic buffer. Cell lysis was performed in a buffer of 100 mM Tris (pH 7.5) 1 mM EDTA, 1 mM EGTA, 0.5 mM Na 3 VO 4 , 10 mM sodium βglycerophosphate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate and 1% Triton X-100. DNA was purified from nuclear extracts by phenol-chloroform extraction and ethanol precipitation. Cellular lysates, DNA samples and incubation medium were analyzed for platinum levels by inductively-coupled plasma mass spectrometry (ICP-MS).
Quantitative RT-PCR analysis
HCT-116 cells were treated for 48 h with IC 50 concentrations of drugs, followed by isolation of mRNA as described (20) . Briefly, total RNA was reverse-transcribed before real-time quantitative PCR amplification using the ABI Prism 7900 Sequence Detection System (Perkin-Elmer Applied Biosystems). The transcripts of the gene coding for the TATA box-binding protein (TBP; a component of the DNA-binding protein complex TFIID) were used as the endogenous control RNA for normalization. Results were expressed as N-fold differences in target gene expression relative to the TBP gene. The mRNA expression of ERCC1, XPA, XPC, PARP1, XRCC1, RAD50, BRCA1, DNA-PK-cs, XRCC6, MSH2, MLH1, BCL2, PUMA, COX2, CDKN1A/p21, ABCB1, ABCC1, GSTP1 was evaluated in a panel of 10 cancer cell lines. Thermal cycling was performed with an initial denaturation step at 95 °C for 10 min, and 50 cycles of 15 s at 95 °C and 1 min at 65 °C. Experiments were performed in duplicate.
Statistical analysis
Statistical analyses were performed with Instat and Prism software (GraphPad, San Diego, USA). Results are expressed as the mean ± standard deviation of at least three experiments performed in duplicate. Means and standard deviations were compared using the Student's t-test (two-sided p value).
Results
Antiproliferative effects of single agent pyriplatin in a panel of human cancer cell lines
The potential anticancer activity of pyriplatin was tested at the National Cancer Institute using the NCI-60 tumor cell line panel screen. Results are shown in Supplementary Figure S1. Analysis of these results using the online COMPARE algorithm revealed that the antiproliferative profile of pyriplatin was not similar to those of cisplatin or oxaliplatin. The best correlation with a platinum compound in the NCI database was with "(carboxyphthalato) platinum" (NSC #S748451), with a correlation coefficient of 0.396. These data suggest that pyriplatin may have a mechanism of action that differs from classical platinum drugs.
Pyriplatin was further evaluated in comparison with cisplatin and oxaliplatin using a well-characterized panel (21) of 10 cancer cell lines of different tissue origins (colorectal, breast, melanoma, ovarian, non-small cell lung). Cells were exposed for 24 h to pyriplatin (0.46-1000 µM), cisplatin (0.1-160 µM), or oxaliplatin (0.1-160 µM) and assessed for cytotoxicity by the MTT assay. Cell counting and the sulforhodamine B assay (data not shown) confirmed the results of the MTT-based antiproliferative assays, shown in Table 1 as IC 50 concentrations. The cytotoxicity profile for pyriplatin, shown in difference plots in Figure 2 , was clearly different from those of both cisplatin and oxaliplatin.
To study the effects of duration of pyriplatin exposure on cell proliferation, we used the cell line in which pyriplatin showed the greatest antiproliferative effect ( Figure   1 ). HOP-62 cells were treated for 1, 2, 5, 24, 48, or 72 h with pyriplatin, cisplatin or oxaliplatin, and then post-incubated for an additional 48 or 72 h period (as described above) in drug-free medium. Pyriplatin displayed dose-and time-dependent antiproliferative effects in HOP-62 cells, with a 72-h exposure producing the lowest IC 50 value obtained for pyriplatin (IC 50 = 24.3, Figure 3 ). The IC 50 of pyriplatin was only 15fold higher than that of cisplatin at 1 and 2 h, indicating that pyriplatin is clearly able to exert cytotoxicity after a short incubation period, unlike oxaliplatin. The difference between pyriplatin and cisplatin increased at 5 h (IC 50 of pyriplatin was 36-fold that of cisplatin) and at 24 h (53-fold difference), suggesting that pyriplatin loses efficacy over time relative to cisplatin.
Pyriplatin mechanism of action
To investigate the mechanism of pyriplatin cytotoxicity, cell cycle analyses were performed in HCT-116 and MCF7 cell lines. All three platinum compounds caused dosedependent progressive accumulation of cells in the G2/M phases (see Figure 4A and Table 2 ). The percentage of apoptotic cells peaked at 24 h after drug washout for both cisplatin and pyriplatin-treated cells (24hR), and at 48h drug washout following oxaliplatin treatment (48hR). The detection of apoptosis 48 h after the start of exposure to cisplatin or 72 h after the beginning of incubation with oxaliplatin are in line with previously published results (22, 23) . The peak of apoptosis in cells treated with pyriplatin corresponded to the maximal apoptotic response to cisplatin, suggesting that pyriplatin acts more quickly than oxaliplatin to induce cell death.
The effects of pyriplatin treatment on DNA damage response pathways related to cell cycle disruption and induction of apoptosis were explored by measuring levels of H2AX and Chk2 phosphorylation, p21 expression, and poly (ADP-ribose) polymerase (PARP-1) cleavage in HOP-62 cells by Western blotting after treatment with platinum at the IC 50 concentrations. As a downstream substrate of ATM (24) and ATR (25) , Chk2 is phosphorylated as part of the cellular response to cisplatin-induced DNA double-strand breaks (24) . Phosphorylated H2AX (γ-H2AX) forms part of the repair complex that assembles at the site of DNA double-strand breaks and serves as a marker of DNA damage signaling (26) . Cleavage of PARP-1 is observed in cells undergoing apoptosis (27) and produces two fragments of 89 and 24 kDa. Multiple roles of p21 and PARP-1 are also described in the context of DNA repair, regulation of cell cycle, apoptosis and gene transcription.
As shown in Figure 4B , increases in p21 and PARP levels as well as slight PARP cleavage were seen after exposure to pyriplatin for 24 h. γ-H2AX and Chk2 phosphorylation at Thr 68 were detected following 24 h treatment with all three platinum compounds. Two bands were observed for γ-H2AX and persisted 72 h after removal of the platinum-containing medium, corresponding to γ-H2AX at 15 kDa and ubiquitylated γ-H2AX at 25 kDa. The band at 25 kDa is shown in Figure 4B and both bands are presented in Figure S3 . The high endogenous expression of phosphorylated H2AX in some tumor cell lines, including HOP-62, complicates the identification of induced DNA breaks using the band at 15 kDa (28, 29) . The 25 kDa band is a ubiquitylated form of γ-H2AX, which is induced by the recently identified E3 ubiquitin ligase RNF168 (30) . The 25 kDa band appears following cisplatin treatment of HCT-116 cells grown on fibronectin (31) , and it is also induced upon cisplatin, oxaliplatin, or pyriplatin treatment of HOP-62 cells. Interestingly, ubiquitin-conjugated H2AX appear to accumulate at sites of DSBs, forming nuclear foci (30, 32) . Ubiquitylation of histone H2AX is also critical for recruitment of important mediators of the DNA damage response, such as the MRN complex (MRE11, RAD50, and NBS1), the p53-binding protein 1 (53BP1) and BRCA1 (32, 33) . Following DNA damage, the chromatin modifier ubiquitin ligase RNF168 colocalizes with γ-H2AX at DNA lesions and increases ubiquitylation of chromatinassociated proteins at the lesion site, promoting a downstream response to the DNA damage (30) . The phosphorylation of γ-H2AX and Chk2 suggests the formation of DNA double strand breaks and indicates apoptotic DNA fragmentation or early DNA damage signaling events in response to treatment with pyriplatin. The pyriplatin-induced DNA damage-dependent ubiquitination of H2AX that is described indicates induction of a downstream DNA damage response to cell treatment with pyriplatin.
Molecular determinants of pyriplatin activity
Platinum levels on nuclear DNA were determined after exposure of HCT-116 cells to 10 µM pyriplatin for 2, 6, 24, and 48 h. Data were also obtained from cells exposed for 2h treatment followed by a 22-h incubation in platinum-free medium. Table 3 and Overall, pyriplatin forms fewer DNA adducts than oxaliplatin and cisplatin, which may play a role in the reduced cytotoxicity of pyriplatin relative to the two established drugs. On the other hand, although pyriplatin is 66-to over 200-fold less potent than cisplatin and oxaliplatin, respectively, at 24 h in HCT-116 cells, the difference in DNA adduct formation is not as stark, suggesting that each adduct of pyriplatin is less toxic than adducts of either cisplatin or oxaliplatin.
It was recently shown that exposure of colon cancer cells to oxaliplatin and cisplatin induced significant changes in expression of several genes implicated in drug transport, DNA repair, and cell cycle regulation (34) . We compared the genetic effects induced by pyriplatin with those of oxaliplatin and cisplatin in the HCT-116 cell line. The mRNA levels encoded by selected genes involved in nucleotide excision repair (ERCC1, XPA, XPC), base excision repair (PARP1, XRCC1), homologous recombination (RAD50, BRCA1), mismatch repair (MSH2, MLH1), apoptosis (PUMA, CDKN1A/p21, COX2), transport (MDR1/ABCB1, ABCC1, GSTP1) and TOP2A, Ki67, and NEK2 were evaluated by RT-PCR after a 48-h exposure to pyriplatin, cisplatin, or oxaliplatin at IC 50 concentrations. As shown in Figure 5 CDKN1/p21 mRNA expression was significantly induced following 48-h pyriplatin exposure (>3 fold). CDKN1/p21 mRNA levels were also induced after exposure to cisplatin and oxaliplatin, which is a well-characterized response to these drugs (35, 36) . Additionally, induction of p21 is associated with cisplatin resistance in human testicular cancer (37) . Pyriplatin also significantly decreased ERCC1 (2-fold decrease) expression. In contrast, exposure to cisplatin slightly increased the ERCC1 mRNA level ( Figure 5 ), whereas exposure to oxaliplatin had little effect on ERCC1 mRNA. Pyriplatin-DNA adducts are repaired less efficiently by nucleotide excision repair than adducts of cisplatin with DNA (intrastrand d(GpG) crosslink) according to mammalian cell free extract-based assays (13) . ERCC1 levels may not be elevated in response to pyriplatin treatment because pyriplatin can largely evade repair by the ERCC1-associated nucleotide excision repair pathway The mRNA levels of other genes studied were not significantly affected ( Figure 5 and data not shown).
The potential predictive role of various genes associated with pyriplatin sensitivity or resistance was investigated by plotting mRNA expression levels of 21 genes in the panel of 10 cell lines as measured by RT-PCR against pyriplatin IC 50 values ( Figure 6 ).
In this case, cells were not treated with platinum prior to RT-PCR analysis. Although low levels of ERCC1 mRNA, but not necessarily the ERCC1 protein, are correlated with favorable responses of patients to a modified FOLFOX (biweekly oxaliplatin plus 5-FU and folinic acid) regimen (38) , levels of ERCC1 mRNA were not correlated with response to pyriplatin. Cells with high levels of RAD50 mRNA are more resistant to pyriplatin (r 2 = 0.35), suggesting that double-strand breaks may play a role in the cellular consequences of pyriplatin-DNA lesions. Cells with high levels of mRNA coding for GSTP1 are also more resistant to pyriplatin (r 2 = 0.38), indicating possible cellular inactivation of pyriplatin by modification with glutathione. Genetic factors GSTP1 and RAD50 are slightly correlated with sensitivity to pyriplatin and may serve as predictive factors of response.
Pyriplatin in combination with other anticancer agents
The effect of administering pyriplatin prior to, subsequently to, and simultaneously with five commonly used anticancer agents in the HT29 and OVCAR-3 cell lines was evaluated after 24 h exposure and interpreted using the Chou and Talalay method. The colon adenocarcinoma HT29 and ovarian adenocarcinoma OVCAR-3 cell lines were chosen because they represent two cancers for which platinum drugs are commonly effective; they have similar doubling times (20 h vs. 30 h) and relatively low sensitivity to pyriplatin ( Table 1 ). Agents that had previously shown synergy in combination with platinum drugs were selected (17, 18) and combinatorial indices (CI) were calculated. A CI of less than 1, suggests that two drugs exert antiproliferative effects via separate mechanisms of action. Additive effects indicate that two drugs act via similar mechanisms of action.
A summary of pyriplatin-based combinations is shown in Table 4 . Paclitaxel showed synergy (CI<1) when administered prior to pyriplatin in both cell lines. Similar to results for oxaliplatin and cisplatin (2) , effects suggestive of synergy between pyriplatin and cisplatin were observed upon simultaneous addition of pyriplatin and cisplatin to cells (Table 4 ). Gemcitabine had antagonistic effects in both cell lines and with all schedules other than simultaneous exposure in HT29 cells. The pyriplatin cytotoxicity profile is distinct from that of both cisplatin and oxaliplatin in a panel of 10 well-characterized cell lines and by the NCI single-dose screen. Although the IC 50 values are 16 to 270 times higher for pyriplatin than for cisplatin or oxaliplatin, it is clear that the cell lines in which pyriplatin is most active (IGROV1, HOP-92, HOP-62, and COLO205) differ from those in which oxaliplatin is most active (HCT-116, OVCAR3, HOP-92, and MCF7) or those in which cisplatin is most active (HCT-116, HOP-92, HOP-62, and OVCAR3), as shown in the difference plots in Figure 2 and in Table 1 . As is the case for cisplatin, the first cytotoxic effects of pyriplatin are seen as soon as one hour after the start of treatment, at which point pyriplatin is only 15-fold less toxic than cisplatin. Pyriplatin activity at 1 and 2 h contrasts with the relatively low activity of oxaliplatin, which must lose the oxalate prior to exerting cytotoxic action and is significantly less active after 1 or 2 h than after 5 h or longer. amines. The X-ray structure of transcribing RNA polymerase II stalled at a site-specific pyriplatin-DNA adduct (15) is valuable for the purpose of predicting which new compounds will improve the transcription inhibition aspect of pyriplatin, an activity that is crucial to DNA damage signaling and eventual triggering of apoptosis. A research program based on pyriplatin as a lead compound has already yielded compounds with significantly improved cytotoxicity compared to pyriplatin as well as cisplatin (39) .
Discussion
The cellular processing of platinum drugs involves a large number of cellular events that may play a role in the ultimate efficiency of these drugs: uptake and efflux, DNA adduct formation, recognition and repair of adducts, and signal transduction of DNA damage. In terms of molecular determinants of pyriplatin sensitivity, a slight correlation of pyriplatin IC 50 with GSTP1 mRNA levels in untreated cells may indicate possible cellular inactivation of pyriplatin by glutathione modification. Levels of ERCC1 mRNA in untreated cells were not correlated with pyriplatin IC 50 , which contrasts with the fact that low levels of ERCC1 mRNA are used to identify patients who are likely to respond well to a modified FOLFOX (biweekly oxaliplatin plus 5-FU and folinic acid) regimen (38) .
Previously it was shown (25) that exposure of colon cancer cells to cisplatin and oxaliplatin can induce expression of several genes implicated in drug transport, DNA repair, and cell cycle regulation. We compared the genetic effects induced by pyriplatin with those induced by cisplatin and oxaliplatin in HCT-116 cells. Significant increases in p21 expression were seen for all three platinum compounds whereas ERCC1 expression decreased in response to pyriplatin and increased in response to cisplatin exposure.
Because a high amount of ERCC1 is associated with resistance to cisplatin (40) (41) (42) , the decrease in ERCC1 mRNA upon treatment with pyriplatin indicates a difference in cellular resistance to the two compounds. The difference in ERCC1 expression, coupled with previous results showing that pyriplatin-DNA adducts evade repair by the nucleotide excision repair pathway as compared with repair of cisplatin-DNA adducts (13) , supports the case that differential repair of cisplatin and pyriplatin adducts contribute to the different activity in our cell line panel.
The potential for use of pyriplatin in combination with other anti-cancer compounds was explored in terms of the antiproliferative potential of paclitaxel, gemcitabine, SN38, cisplatin, and 5-FU combinations. In both cell lines tested, pyriplatin was synergistic when administered simultaneously with cisplatin, as is seen when cells are treated with both cisplatin and oxaliplatin (2) . Synergy implies a molecular mechanism of action distinct from that of cisplatin.
In conclusion, although pyriplatin is not likely to be developed due to its low cytotoxicity, it remains a promising lead compound for the generation of novel drug candidates with different cytotoxicity profiles from those of platinum drugs currently in use. Data are presented as the median CI value and the 95% confidence interval. Schedule A: 24-h pyriplatin followed by the 24-h combination drug; Schedule B: 24-h combination drug followed by the 24-h pyriplatin; Schedule C: 24-h simultaneous exposure. 
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